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Abstract
The liver X receptors (LXRs) are transcriptional regulators of cellular and systemic cholesterol 
homeostasis. In the setting of cholesterol excess, LXR activation induces the expression of a 
battery of genes involved in cholesterol efflux 1, facilities cholesterol esterification by promoting 
fatty acid synthesis 2, and inhibits cholesterol uptake by the low-density lipoprotein receptor 
(LDLR)3. The fact that sterol content is maintained in a narrow range in most cell types and in the 
organism as a whole suggests that extensive crosstalk between regulatory pathways must exist. 
However, the molecular mechanisms that integrate LXRs with other lipid metabolic pathways, are 
incompletely understood. Here we show that ligand activation of LXRs in liver not only promotes 
cholesterol efflux, but also simultaneously inhibits cholesterol biosynthesis. We further identify 
the long non-coding RNA LeXis as one mediator of this effect. Hepatic LeXis expression is 
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robustly induced in response to western diet feeding or pharmacologic LXR activation. Raising or 
lowering the levels of LeXis in liver affects the expression of cholesterol biosynthetic genes, and 
the levels of cholesterol in the liver and plasma. LeXis interacts with and affects the DNA 
interactions of Raly, a heterogeneous ribonucleoprotein that is required for the maximal expression 
of cholesterologenic genes in mouse liver. These studies outline a regulatory role for a non-coding 
RNA in lipid metabolism and advance our understanding of the mechanisms orchestrating sterol 
homeostasis.
It is well established that the cholesterol biosynthetic pathway is downregulated under 
conditions where sterols are abundant through the inhibition of sterol regulatory element-
binding protein (SREBP) processing4. Interestingly, however, under conditions where 
hepatic cholesterol content was not enriched, activation of LXR with the selective synthetic 
agonist GW3965 also acutely suppressed the expression of sterol synthesis genes in mouse 
liver (Fig. 1a and Extended data Fig. 1a). The effect could not be explained by changes in 
intracellular cholesterol levels, as LXR activation has been shown to lower hepatic 
cholesterol content 5, which would lead to up-regulation of the SREBP-2 pathway.
To investigate the mechanism by which LXRs suppress cholesterol biosynthesis, we 
performed genome-wide transcriptional profiling on primary mouse hepatocytes treated with 
vehicle or GW3965 (Extended data Fig. 1b). The most robustly induced gene in our RNA-
sequencing analysis was a predicted noncoding RNA annotated as 4930412L05Rik 
(Extended data Fig. 1c). Parallel profiling of noncoding and protein-coding transcripts using 
microarrays also identified 4930412L05Rik as the highest induced transcript (Extended data 
Fig. 1d). We named this transcript LeXis (Liver-expressed LXR-induced sequence). 
Interestingly, the LeXis gene locus lies in close proximity to the canonical LXR target gene 
Abca1 in mouse. Analysis of chromatin structure from ENCODE 6–7 indicated that LeXis 
and Abca1 were distinct genes with separate promoters (Fig. 1b). We defined the transcripts 
produced from the LeXis gene using rapid amplification of cDNA ends (RACE) (Extended 
data Fig. 2). LeXis and Abca1 were induced by LXR (GW3965) and RXR (LG268) agonists 
in primary hepatocytes in an LXR-dependent manner (Fig. 1c and Extended data Fig. 3a). 
LeXis was induced in LXRα−/− and LXRβ−/− hepatocytes, indicating that both LXR 
isotypes are capable of regulating LeXis (Extended data Fig. 3b). Induction of LeXis was 
not sensitive to the protein synthesis inhibitor cycloheximide, and was not dependent on 
SREBPs, since 25-hydroxycholesterol (which blocks SREBP processing) also induced 
LeXis (Extended data Fig. 3c and 3d).
Administration of GW3965 to mice induced the expression of LeXis in multiple 
metabolically-active tissues (Fig. 1d and Extended data Fig. 3e). We also observed a 
prominent, LXR-dependent induction of LeXis expression in response to western diet 
feeding, consistent with a potential role for LeXis in the response to cholesterol excess (Fig. 
1e). Despite being physically adjacent, the LeXis and Abca1 loci are regulated 
independently. LeXis was neither expressed at baseline nor induced by LXR in peritoneal 
macrophages, a cell type in which Abca1 expression is prominent (Fig. 1f). A luciferase 
reporter containing the LeXis promoter was induced by LXR/RXR in cotransfection assays 
(Extended data Fig. 3f), and we identified an LXR-response element within the LeXis 
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promoter region that was bound by LXRα in ChIP-qPCR assays (Extended data Fig. 3g). 
The Coding Potential Calculator (CPC) and Coding Non-Coding Index (CNCI) algorithms 
predict low coding potential of LeXis (Extended data Fig. 3h,i). In addition, we found no 
evidence of production of a protein product from LeXis using in vitro transcription-
translation assays (Extended data Fig. 3j).
To explore the function of LeXis in vivo, we transduced mice with adenoviral vectors 
encoding GFP control or LeXis (Fig. 2a and Extended data Fig. 4a). Remarkably, LeXis 
expression decreased serum cholesterol, but not triglycerides, in chow-fed C57BL/6 mice 
(Fig. 2a,b). No differences in liver function tests were observed between the two groups, and 
there was no evidence of ER stress or inflammation (Fig. 2b and Extended data Fig. 4b,c). 
Fractionation of lipoproteins revealed reduced cholesterol in both the LDL and HDL 
fractions in LeXis-expressing mice (Fig. 2c). The effects of LeXis were distinct from the 
consequences of hepatic expression other LXR target genes, such as Abca1 and Idol, which 
raise serum cholesterol89.
Unbiased pathway analysis of global gene expression revealed that the cholesterol 
biosynthetic pathway was strongly downregulated in LeXis-transduced livers (Extended data 
Fig. 4d). These results were validated by real-time PCR (Fig. 2d). These results suggested 
that the cholesterol lowering effects of LeXis were due, at least in part, to suppression of 
cholesterol biosynthesis. Consistent with this interpretation, we observed a strong trend 
towards lower cholesterol content in the livers of mice overexpressing LeXis (Extended data 
Fig. 4e). For reasons that are not yet clear, treatment of isolated primary hepatocytes did not 
faithfully reflect the effects of either LXR agonist treatment or LeXis expression on genes 
linked to sterol synthesis (Extended data Fig. 4f,g).
A reduction in plasma cholesterol suggests an increase in lipoprotein clearance or a decrease 
in sterol production10. To assess the contribution of LDLR to the actions of LeXis, we 
transduced Ldlr−/− mice with control or LeXis–expressing adenovirus. We observed 
decreases in plasma cholesterol levels and hepatic cholesterol content in response to LeXis 
in Ldlr−/− mice, suggesting that the Ldlr is not required for LeXis effects (Fig. 2e and 
Extended data Fig. 4h, i). To assess the contribution of Srebp-2 signaling to LXR-mediated 
inhibition of cholesterologenesis, we administered GW3965 to control or liver-specific Scap 
knockout mice (L-Scap KO)11. Consistent with previous studies 12, GW3965 treatment did 
not alter serum cholesterol levels in control mice (Fig. 2f). Surprisingly, however, GW3965 
increased serum cholesterol levels in L-Scap KO mice, suggesting the loss of a suppressive 
effect (Fig. 2f and 2g). LXR target genes, including LeXis itself, were induced by GW3965 
in both groups; however, the suppression of steroidogenic genes was abrogated in L-Scap 
KO mice (Extended data Fig. 4j). Furthermore, expression of LeXis also failed to lower 
serum cholesterol or to suppress cholesterogenic gene expression in L-Scap KO mice (Fig. 
2h and extended data Fig. 4k).
To address the role of LeXis in the setting of dietary cholesterol challenge, we used 
adenoviral vectors to express shRNA constructs targeting LeXis in mouse liver1314. 
Knockdown of LeXis with either of two different shRNA constructs increased serum HDL 
cholesterol levels in mice fed a western diet (Extended data Fig. 5a–d). There was also an 
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increase in liver cholesterol content in shLeXis-transduced mice (Extended data Fig. 5e). 
Gene expression analysis revealed increased expression of a number of cholesterol 
biosynthetic genes in response to LeXis knockdown (Extended data Fig. 5f). Similar effects 
of LeXis knockdown were observed in mice treated with GW3965 (Extended data Fig. 
5g,h). There was no consistent evidence of ER stress or inflammation in these experiments 
(Extended data Figs. 5i,j,k).
As a complementary acute loss-of-function approach, we utilized antisense oligonucleotides 
(ASOs) to target LeXis expression1516. Three different ASOs that potently blocked hepatic 
LeXis, but not saline or non-targeting ASO controls, increased serum cholesterol levels in 
the setting of LXR activation, with no evidence of hepatotoxicity (Fig. 3a,b and Extended 
data Figs. 5l,m). Furthermore, LeXis ASO administration increased cholesterogenic gene 
expression (Figs 3c).
We generated LeXis-deficient mice to determine the consequences of chronic loss of LeXis 
function (Extended data Fig. 6a–6c). Although serum cholesterol levels in LeXis-deficient 
mice in the setting of LXR activation were not different from controls (Fig. 3d), the 
expression of sterol synthesis genes in the liver was increased (Fig. 3e). Furthermore, LeXis-
null mice had increased hepatic cholesterol content when challenged with western diet (Fig. 
3f). Gross and histologic examination of livers from LeXis-deficient mice null mice showed 
changes consistent with lipid accumulation (Fig. 3g and 3h). In contrast to the acute LXR 
agonist studies above, gene expression analysis of LeXis−/− mice maintained on western 
diet showed a trend toward decreased sterol synthetic gene expression, likely reflecting the 
marked increased hepatic cholesterol content in this setting (Extended data Fig. 6d).
To begin to understand how LeXis was influencing hepatic metabolism, we analyzed its 
subcellular localization. LeXis was almost exclusively located in the insoluble nuclear pellet 
in fractionation studies, along with the known nuclear lncRNAs XIST and histone H3 (Fig. 
4a). Single molecule RNA fluorescence in-situ hybridization with LeXis-specific probes 
further confirmed its nuclear localization (Fig. 4b).
Its presence in the nucleus suggested that LeXis might influence, and therefore we tested its 
ability to impact RNA polymerase II-dependent transcription. Expression of LeXis in mouse 
liver reduced RNA polymerase II engagement at the promoters of Srebf2 and its target genes 
(Fig. 4c). Prior work has shown that nuclear lncRNAs can affect transcription by modifying 
the recruitment of proteins to chromatin 17. We used an unbiased lncRNA:chromatin affinity 
capture technique to pulldown LeXis from mouse liver and identify interacting proteins 
(Extended data Fig. 7a) 18. Analysis of the LeXis interactome by mass spectrometry 
identified the heterogeneous ribonucleoprotein Raly 19 as a binding partner. Similar to 
LeXis, Raly was located in the nuclear pellet (chromatin) fraction of hepatocytes (Extended 
data Fig. 7b). Moreover, an antibody to Raly retrieved LeXis in co-immunoprecipitation 
studies (Extended data Fig. 7c,d).
Raly contains both an RNA-binding domain and a leucine-zipper coiled domain, suggesting 
it may act as a regulatory factor 20. Intriguingly, prior unbiased analysis of gene 
coexpression networks has identified Srebf2 as one of the top genes positively coregulated 
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with Raly 21. Other studies have shown direct binding of Srebp-2 at the Raly promoter 22. 
Unbiased protein homology analysis revealed extensive structural conservation between 
Raly and RNA Binding Protein 14 (also known as CoAA; extended data Fig. 7e)23, a known 
steroid receptor coactivator 24. This led us to hypothesize that Raly may act as 
transcriptional cofactor for genes involved in cholesterol biosynthesis. In line with this idea, 
adenovirus-mediated knockdown of Raly in mouse liver reduced serum cholesterol, 
mimicking the effect of LeXis expression (Fig. 4d and Extended data Fig. 7f). This effect 
was correlated with reduced expression of Srebf2 and its target genes (Fig. 4e and Extended 
data Fig. 7g). Unbiased gene expression profiling of liver revealed that Raly knockdown 
preferentially affected cholesterol biosynthetic pathways (Extended data Fig. 8a,b). The 
effects of Raly were independent of LDLR expression, since they were preserved in Ldlr-
null mice (Extended data Fig. 9a,b). The actions of LeXis in vivo were dependent on Raly, 
since the ability of LeXis to alter serum cholesterol levels and hepatic gene expression was 
impaired in the setting of Raly knockdown (Fig. 4f and extended data Fig. 9c). Finally, 
ChIP-qPCR analysis of mouse liver revealed that Raly associated with cholesterol 
biosynthetic gene promoters, and that Raly occupancy was reduced in the setting of LeXis 
expression (Extended data Fig. 9d).
This work identifies the non-coding RNA LeXis as additional mediator of the complex 
effects of LXR signaling on hepatic lipid metabolism. Our data suggest that LeXis 
contributes to the ability of LXRs to inhibit cholesterol synthesis. It is important to 
acknowledge, however, that the involvement of additional pathways in this crosstalk is not 
excluded by the present work. The demonstration that LeXis expression is responsive to 
dietary cues and can modulate physiologic pathways with links to common diseases expands 
our understanding of the regulatory potential of non-coding RNA. Interestingly, the 
consequences of acute and chronic loss of LeXis expression are only partially overlapping, 
perhaps reflecting compensation in the setting of developmental deletion 25.
Although the rapid sequence evolution of lncRNAs presents a challenge to identifying 
functional counterparts between species 26, Batch Coordinate Conversion between mouse 
and human assemblies revealed moderate conservation of the LeXis genomic sequence in a 
region adjacent to the human ABCA1 gene. An annotated putative lncRNA (TCONS 16452) 
in this region was robustly induced by LXR activation in human hepatocyte cell lines 
(Extended data Fig. 10). In the future it will be of interest to assess if this sequence or an as 
yet to be identified lncRNA is a functional ortholog of LeXis.
 Materials & Methods
 Reagents, Plasmids, and Gene Expression
GW3965 was synthesized as previously described 27. LG268 was from Ligand 
Pharmaceuticals. Oxysterols were purchased from Sigma and used as described 28. 
Simvastatin sodium salt was from Calbiochem. Ligands were dissolved in dimethyl 
sulfoxide before use in cell culture. LeXis was amplified from GW3695-treated primary 
mouse hepatocytes using KOD polymerase (Millipore) and primers designed to provide 
flanking attB sequences and a SacI site at the immediate 3' end. The fragments were then 
cloned into pDONR221 using the Gateway system and the minimal SV40 polyadenylation 
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sequence was inserted at the SacI site. For transient transfections and viral vector production 
the entry clone was transferred into the pAd/CMV/V5-DEST Gateway vector by LR 
recombination. We estimate transcription from this vector to append 109 nucleotides at the 5' 
end, and 29 nucleotides at the 3' end of the cloned LeXis sequence. To obtain the shLeXis 
adenovirus, we used BLOCK-iT kit as described (Invitrogen) 3. Briefly, Invitrogen based 
software was used for original nucleotide generation targeting the LEXIS fragment and 
cloned into pENTR/U6. The resulting pENTR/U6-LEXIS shRNA plasmids were tested for 
their ability to inhibit overexpressed LEXIS in transient transfection experiments in 
HEK293T cells and then transferred by LR recombination into the pAd/BLOCK-iT-DEST 
destination vector for viral particle generation. Viruses were amplified, purified, and tittered 
by Viraquest. For gene expression analysis, RNA was isolated using TRIzol reagent 
(Invitrogen) and analyzed by real-time PCR using an Applied Biosystems 7900HT sequence 
detector or Applied Biosystems Quant Studio 6 Flex. Results are normalized to 36B4 or 
cyclophilin. Immunohistochemical staining of paraffin-embedded livers were done by the 
UCLA Translational Pathology Core Laboratory.
 Animals and Diets
All animals (C57Bl/6, greater than 10 generations backcrossed) were housed in a 
temperature-controlled room under a 12-hour light/12-hour dark cycle and under pathogen-
free conditions. For adenovirus experiments aged matched mice were purchased from 
Jackson Lab. Littermates were manually randomized to different treatment groups. 
Investigators were blinded to group allocation for some but not all studies. LXRα−/−, LXRβ
−/−, and LXRαβ−/− mice were originally provided by David Mangelsdorf, University of 
Texas Southwestern Medical Center, Dallas, Texas, USA. Floxed SCAP−/−mice were 
previously described 29. LeXis global knockout Mice were generated at UCDavis KOMP 
using strategy outlined in Extended data Fig. 6). Mice were fed a chow diet except as 
indicated where mice were placed on a Western diet (21 percent fat, 0.21 percent 
cholesterol; D12079B; Research Diets Inc.) or were gavaged with either vehicle or 40 mg/kg 
of GW3965. Livers were harvested four hours after the last gavage. We measured cholesterol 
and triglycerides as previously described 30. For adenoviral infections, age-matched (9–11 
weeks old) male mice were injected with 2.0 × 109 PFU by tail-vein injection unless 
otherwise specified. Mice were sacrificed six days later following a six-hour fast. At the time 
of sacrifice liver tissue and blood was collected by cardiac-puncture and immediately frozen 
in liquid nitrogen and stored at –80°. Liver tissue was processed for isolation of RNA and 
protein as above. Generation 2.5 constrained ethyl ASOs, synthesized as described 
previously31, were IP administered 3 doses at a concentration of 25 mg/kg along with 40 
mg/kg of GW3965. Animals were sacrificed on day 6 or day 8 as indicated in figure legends. 
The majority of experiments were performed using male mice. All animal experiments were 
approved by the UCLA Institutional Animal Care and Research Advisory Committee.
 Cell culture
Primary peritoneal macrophages were isolated four days after thioglycollate injection and 
prepared as described 32. Mouse primary hepatocytes were isolated as previously described 
and cultured in William’s E medium with 5 percent FBS 28. Peritoneal cells were incubated 
in 0.5 percent FBS in DMEM, with 5 µM simvastatin and 100 µM mevalonic acid. Five to 
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eight hours later, cells were pretreated with DMSO or appropriate ligand overnight. In vitro 
translation assay was performed using TnT Coupled Transcription/Translation System 
(PROMEGA) according to the manufacturer’s protocol. The cell lines HEK293T, 
HEK293A, Hepa1-6 were originally obtained from ATCC. All cells were tested for 
mycoplasma contamination.
 RACE
The 5' and 3' ends of the LeXis transcript were defined using mouse liver RNA and the 
FirstChoice RLM-RACE kit (Ambion) according to manufacturer's protocol, with 
modifications. Briefly, for the 5' RACE, degraded mRNA 5' ends were dephosphorylated 
with CIP and then full-length mRNA was decapped with TAP. Following 5'RACE adapter 
ligation, reverse transcription was performed using SuperScriptIII First-Strand Synthesis 
system (Invitrogen) and LeXis-specific primers. For the 3’RACE, the RNA was reverse 
transcribed using SuperScriptIII First-Strand Synthesis system (Invitrogen) and the adapter-
linked oligo dTs. The resulting cDNA was amplified by nested PCR across a 55–65 °C 
melting temperature gradient using KOD polymerase (Millipore), with the inner primers 
containing attB sequences. Aliquots of reactions were inspected on 1% agarose gels for 
product size and abundance. Products of select PCR reactions were purified using 
NucleoSpin Gel and PCR Cleanup kit (Clontech) and were inserted into pDONR221 by 
Gateway cloning. Cloned fragments were sequenced and then aligned to the mouse genome 
with the BLAST analysis tool.
 RNA fractionation
PAd/CMV-LeXis vector was transfected into Hepa1-6 cells using BioT reagent (Bioland 
Scientific LLC) and 24 h later subcellular RNA fractions were obtained according to the 
protocol of Bhatt et al 33. Lysate aliquots were inspected for fractional purity by Western 
blotting with antibodies against α-tubulin, SNRP70 and histone H3 as cytoplasmic, 
nucleoplasmic and chromatin bound markers, respectively.
 RNA Sequencing
RNA sequencing libraries, starting with 500 ng total RNA, were constructed with the TruSeq 
RNA Sample Prep Kits from Illumina on RNA isolated from primary hepatocytes treated 
with or without GW3965. Samples were indexed with adapters and submitted for paired-end 
2 × 100-bp sequencing in Illumina HiSeq2000. RNA-seq reads were aligned with 
TopHatv2.0.2 to the mouse genome, version mm9 34. The Tophat alignment rate was 85 
percent, resulting in an average of 65 million reads per sample. Transcripts were assessed 
and quantities were determined by Cufflinks v2.0.2, using a GTF file based on Ensembl 
mouse NCBI37. Comparison expression levels were made using FPKM values using 
Cuffdiff from the Cufflinks package 35. Data analysis performed by UCLA DNA Microarray 
Core.
 Lipid Analysis
Tissue lipid was obtained using a Folch extraction. Briefly, chloroform extracts were dried 
under nitrogen and solubilized in water. Tissue and serum cholesterol and triglycerides were 
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determined using a commercially available enzymatic kit (Wako). Hepatic cholesterol 
content was normalized to liver weight and protein concentration. Mice were fasted for at 
least 6 hours prior to blood collection and sacrifice. Plasma lipoprotein fractions were 
analyzed by FPLC.
 Microarray
For cDNA microarray analysis, primary hepatocytes cells were treated as indicated above 
with either DMSO or GW3695. These samples were from an independent cohort from those 
submitted for RNA-seq. For each condition, two independent samples were processed. 
Transcriptional profiling was performed at the University of California, Los Angeles, 
microarray core facility by using Agilent SurePrint G3 Gene Expression array. Data were 
analyzed using GeneSpring software (Agilent Technologies) and David 36.
 ChIP
Chip studies were performed as described elsewhere 37. Briefly mouse livers were cross-
linked using a final formaldehyde concentration of 1% at room temperature for 10 minutes. 
The reaction was quenched with the addition of glycine. For sonication, 0.3 ml (1/3) of 
nuclear lysate was sonicated for 25–30 cycles 30 seconds on 30 seconds off at 4°C with 
BioRuptor twin sonicator (Diagenode). Sonicated Chromatin was incubated overnight at 4°C 
with control IgG or 25 ug of Anti-LXR alpha antibody [PPZ0412] - ChIP Grade (ABCAM), 
Pol II, Anti-Raly antibody [EPR10121] (ABCAM), or Pol II Antibody (N-20) X (Santa Cruz 
Biotechnology). Protein A Dynabeads (50 µl per IP sample) were added for 4 hours. After 
incubation beads were washed with wash buffer A (50 mM HEPES pH 7.9, 140 mM NaCl, 1 
mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 1x Protease Inhibitors 
freshly added), buffer B (50 mM HEPES pH 7.9, 500 mM NaCl, 1 mM EDTA, 1% Triton 
X-100, 0.1% Na-deoxycholate, 0.1% SDS) and finally LiCL buffer (20 mM Tris pH 8.0, 250 
mM LiCl, 1 mM EDTA, 0.5% Na-deoxycholate, 0.5% NP-40). Reverse crosslinking was 
performed at 60°C overnight, with 1000rpm mix and DNA was extracted using a phenol-
chloroform phase lock tube (5 PRIME) or Nucleospin PCR cleanup column (Macherey-
Nagel). A standard curve for PCR was generated from serial dilutions of input samples and 
data expressed as percentage of input.
 ChIRP
Chirp was performed as described by Chu et al 18. Briefly, mouse livers were cross-linked 
using glutaraldehyde. After glycine quenching, the nuclear lysate was sonicated for 25–30 
cycles 30 seconds on 30 seconds off at 4°C with BioRuptor twin sonicator (Diagenode). 
LeXis and LacZ pulldown probes with BiotinTEG at 3’ were designed by Biosearch 
Tecnologies (see supplementary information) and allowed to hybridize overnight with 
sonicated chromatin at 37 °C (100 pmol probe per 1 mL chromatin). Following 
hybridization, C1 Dynabeads (Life Technologies) were added and incubated for 30 minutes. 
For protein elution for mass spectrometry analysis, washed beads were resuspended in 3× 
original volume of DNase buffer (100 mM NaCl and 0.1% NP-40), and protein was eluted 
with a cocktail of 50 mM triethyl ammonium bicarbonate, 12 mM sodium lauryl sarcosine, 
and 0.5% sodium deoxycholate supplemented with 100 ug/ml RNase A (Sigma-Aldrich) and 
0.1 Units/microliter RNase H (Epicenter), and 100 U/ml DNase I (Invitrogen). For RNA 
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isolation, beads were resuspended in protensase K buffer (100 mM NaCl, 10 mM TrisCl pH 
7.0, 1 mM EDTA, 0.5% SDS, 5% by volume Proteainse K Ambion AM2546 20 mg/ml) and 
incubated at 50 °C followed by Trizol isolation and DNase treatment.
 Single molecule RNA FISH
Custom Stellaris FISH probes were designed against LeXis. Stellaris probe set labeled with 
CAL Fluor Red 610 and RNA FISH performed as described by Raj el al 38. Briefly, 
hepatocytes were fixed with 3.7% formaldehyde in 1X PBS followed by 70% ethanol 
treatment to permeabilize cells. Cells were washed with 10% formamide in 2X SCC 
followed by treatment in humidified chamber with addition of probes (125 nM) in 
hybridization buffer (100mg/ml dextran sulphate and 10% formamide in 2X SSC). Cells 
were incubated in dark at 37 °C for 4 hours. Dapi Nuclear stain (5 ng/ml) was applied after 
washing with 10% formamide in 2X SCC. Images obtained using a Zeiss Z1 AxioObserver 
fluorescent microscope.
 Statistical analysis
A non-paired student t-test was or ANOVA was used to determine statistical significance, 
defined at P-value < 0.05. Unless otherwise noted, error bars represent standard deviations. 
Experiments were independently performed at least twice. Sample size is based on statistical 
analysis of variance and prior experience with similar in vivo studies.
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 Extended Data
Extended data Figure 1. Identification of LeXis as an LXR-responsive lncRNA
a. Real-time PCR analysis of gene expression in livers from mice gavaged with 40 mg/kg 
GW3965 for 2 days. Mice were fasted for 4 hours prior to harvest (N=4/group). Values are 
means ± SEM. * P < 0.05; ** P < 0.01 and *** P < 0.001 (unpaired two-tailed t-test). b. 
Volcano plot of RNA-seq results from primary hepatocytes treated for 16 hours with 
GW3965 (GW, 1µM). c. Relative expression of select LXR target genes identified in the 
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RNA-seq study shown in b. Fold change represents ratio of transcript expression in GW3965 
over DMSO treatment samples. Cut off fold induction of 1.1 used (total 4708 transcripts 
induced). d. Heat map representation of the results of transcriptional profiling (Agilent 
SurePrint G3 Gene Expression arrays) of primary hepatocytes treated with 1µM GW3965 16 
hours. Data were analyzed using GeneSpring software.
Extended data Figure 2. Schematic of the LeXis gene locus and its RNA transcripts
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a. UCSC genome browser view of RNAseq transcriptional signatures at the Abca1/LeXis 
locus in mouse primary hepatocytes treated with GW3965 (GW, 1 µM) for 16 hours. b. 
Exon structure of major and minor LeXis transcripts identified by RACE, aligned for 
comparison to existing annotation in the indicated databases.
Extended data Figure 3. Regulation of LeXis expression
a. Real-time PCR analysis of primary mouse hepatocytes from WT or Lxrαβ−/− mice 
treated with 1 µM GW3965 and/or 50 nM LG268. Results are representative of four 
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independent experiments. Values are means ± SD. b. LeXis expression in primary mouse 
hepatocytes from WT, Lxrα−/−, Lxrβ−/− or Lxrαβ−/− mice treated with GW3965 and 
LG268. Results are representative of three independent experiments. Values are means ± SD. 
c. LeXis expression in primary hepatocytes treated with GW3965 and LG268 in presence or 
absence of the protein synthesis inhibitor cycloheximide (Chx, 1 µg/µl). Results are 
representative of three independent experiments. Values are means ± SD. 
(Chx=Cyloheximide). d. LeXis expression in primary hepatocytes treated with GW3965 and 
LG268 (LG, 50 nM) in the presence or absence of 25-hydroxycholesterol (25OH, 2.5 µM). 
Results are representative of three independent experiments. Values are means ± SD. e. Gene 
expression in tissues from C57BL/6 mice gavaged with 40 mg/kg GW3965 for 3 days. N=5/
group. Values are means ± SEM. * P < 0.05; ** P < 0.01; *** P <0.001 and **** P <0.0001 
(unpaired two-tailed t-test). f. Relative firefly luciferase activity measured from the pgl4.10 
vector or pgl4.10 with the LeXis promoter cloned upstream of luciferase. Reporters were 
cotransfected in 293 cells and treated with GW3965 for 24 hours. Activity is normalized to 
Renilla luciferase internal control. g. Analysis of LXRα binding to the LeXis promoter in 
mouse liver by ChIP-qPCR. Schematic shows primer pair positions relative to the LXREs in 
the LeXis, and Abca1 (positive control) promoters. Primers flanking a region of the MAP 
kinase I promoter served as a negative control. Chip values are presented as percentage of 
input DNA. (N=4/group). Values are means ± SEM. h. Prediction of coding potential using 
the Coding-Non-Coding Index (CNCI) software. Negative value indicates low coding 
potential. i. Comparison of protein coding potential using CPC score for LeXis, the 
noncoding gene HOTAIR, and control protein-coding transcripts. j. In vitro translation of 
LeXis and luciferase control RNAs.
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Extended data Figure 4. LeXis modulates the expression of genes liked to sterol synthesis
a. Gene expression in livers harvested after 6 days of transduction with pAd-GFP or pAd-
LeXis (N=8/group). All values are means ± SEM. b. Serum alanine aminotransferase 
activity in chow-fed mice transduced with pAd-GFP or pAd-LeXis for 6 days. N=8/group. 
All values are means ± SEM. c. Gene expression in livers harvested after 6 days of 
transduction with pAd-GFP or pAd-LeXis (N=8/group). All values are means ± SEM. d. 
Unbiased pathway analysis (GeneSpring software) of the results from transcriptional 
profiling of livers treated with pAd-GFP or pAd-LeXis. N=4/group. e. Hepatic cholesterol 
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content normalized to liver mass in WT mice transduced with pAd-GFP or pAd-LeXis 
(N=8/group). All values are means ± SEM. f. Gene expression in mouse hepatocytes treated 
overnight with 1 µM GW3965. Results are representative of two independent experiments. 
Values are means ± SD. g. Gene expression in mouse hepatocytes treated overnight with 
AdGFP or AdLeXis for 24 hours. Results are representative of two independent 
experiments. Values are means ± SD. h. Cholesterol levels in pooled fractionated serum 
from LDLR−/− mice transduced with pAd-GFP or pAd-LeXis. i. Hepatic cholesterol 
content normalized to liver mass in LDLR−/− mice transduced with pAd-GFP or pAd-LeXis 
(N=8/group). All values are means ± SEM. j. Gene expression in livers from chow-fed WT 
or L-Scap KO (KO) mice gavaged with 40 mg/kg GW3965 for 2 days. (N=5(WT Veh), 
8(WT GW), 5(KO Veh), 7(KO GW)). All values are means ± SEM. k. Gene expression in 
livers from L-Scap KO chow-fed mice transduced with Ad-GFP or Ad-LeXis for 6 days. 
(N=5/group). All values are means ± SEM.* P < 0.05; ** P < 0.01 (unpaired two-tailed t-
test).
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Extended data Figure 5. Inhibition of LeXis expression alters serum cholesterol level
a. In vitro validation of LeXis knockdown using shLeXis1 and shLeXis8 vectors. Results are 
representative of three independent experiments. Values means ± SD. b. Total serum 
cholesterol measured in C57Bl/6 mice fed 2 weeks of western diet and transduced with 
adenovirus shCtrl or shLeXis8 for 6 days (N=6–8/group). c. Cholesterol levels in pooled 
fractionated serum from mice transduced with shCtrl or shLeXis adenovirus. d. Total serum 
cholesterol from male C57BL/6 mice fed western diet for 2 weeks and then transduced with 
control (shCtrl) or adenoviral vectors expressing shRNA targeting LeXis (shLeXis1) (N=8/
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group). e. Hepatic cholesterol content normalized to liver mass for the mice shown in d (N= 
8(shCtrl), 7(shLeXis1)). f. Gene expression in livers of mice fed western diet for 2 weeks 
and then transduced with shCtrl or shLeXis (N= 8(shCtrl), 7(shLeXis1)). Values are means 
± SEM. g. Total plasma cholesterol levels in chow-fed C57Bl/6 mice transduced with shCtrl 
or shLeXis adenovirus and treated with 40 mg/kg GW3965 by gavage for 6 days (N=8/
group). h. Gene expression in livers of chow-fed C57Bl/6 mice transduced with shCtrl or 
shLeXis adenovirus and treated with 40 mg/kg GW3965 by gavage for 6 days (N=8/group). 
Values are means ± SEM. i. Serum alanine aminotransferase activity from mice in h. All 
values are means ± SEM. j. Serum alanine aminotransferase activity from mice in d. All 
values are means ± SEM. k. Gene expression in livers of mice fed western diet for 2 weeks 
and then transduced with shCtrl or shLeXis (N= 8(shCtrl), 7(shLeXis1)). . Values are means 
± SEM. l. Serum alanine aminotransferase activity from C57BL/6 mice on chow diet 
administered ASOs IP at 25 mg/kg on days 1, 4, and 7, and gavaged with GW3965 40 
mg/kg on days 4, 7 and 8 (N=5/group). All values are means ± SEM. m. Total serum 
cholesterol from C57BL/6 mice on chow diet ASOs administered ASOs IP at 25 mg/kg on 
days 1, 3, and 5 and gavaged with 40 mg/kg GW3965 on days 5 and 6 (N=8/group). * P < 
0.05; ** P < 0.01; *** P < 0.001 (unpaired two-tailed t-test (b, d–h, j) and ANOVA with 
multigroup comparison (m)).
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Extended data Figure 6. Generation of global LeXis−/− mice
a. Schematic of knockout strategy. Vector construct designed to ablate entire LeXis 
transcript. Targeted mice were crossed with Flp−/− mice to excise the Neo cassette since it 
contains an active bi-directional promoter. b and c Gene expression (N=3/group) and PCR 
genotyping strategy for LeXis−/− mice. d. Gene expression from C57BL/6 WT or LeXis−/− 
mice placed on western diet for 3 weeks (N=11(WT), 7(LeXis−/−)). All values are means ± 
SEM. * P < 0.05 (unpaired two-tailed t-test).
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Extended data Figure 7. Identification of Raly as a LeXis-interacting protein
a. Complimentary biotin labeled tilling oligonucleotides incubated with cellular extracts 
from liver. Probes sets designed to retrieve LeXis (Lex 1 and Lex 2) or LacZ (LacZ1 and 
LacZ2). Percent input of retrieved LeXis and 36b4 are shown. (N=4/group). Values are 
means ± STD. b. Cellular contents separated into cytoplasmic soluble, nuclear soluble and 
insoluble (pellet) fractions were analyzed by Western blotting with anti-RALY and anti-
histone H3 antibodies. C=Cytoplasm, N=Nucleoplasm, P=Nuclear Pellet. c. Antibodies were 
incubated with cellular lysates from mouse hepatocytes and interaction with endogenous 
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RALY was assessed after immunoprecipitation and Western Blot. d. Complexes from b were 
analyzed for presence of LeXis or GAPDH by RT-qPCR and signals were normalized to 
36b4. (N=4/group). e. Sequence alignment, predicted secondary structure, and 3D model of 
Raly are shown as reported using the Phyre2 web portal (Protein Homology/analogY 
Recognition Engine V 2.0). f. Western blot for Raly from livers transduced with control 
(shCtrl) or adenoviral vectors expressing shRNA targeting Raly (shRaly) (N=Pooled 4 
animals/group). g. Gene expression from liver from 14-week old chow-fed male C57Bl/6 
mice transduced with control (shCtrl) or adenoviral vectors expressing shRNA targeting 
Raly (shRaly) (N=8/group). All values are means ±SEM.
Extended data Figure 8. Knockdown of Raly preferentially affects pathways link to cholesterol 
metabolism in mouse liver
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a and b. Most significant Gene Ontology terms from microarray analysis from livers treated 
with shCtrl or shRaly. Analysis performed using Genespring and DAVID.
Extended data Figure 9. Raly is required for LeXis mediated effects on cholesterogenesis
a. Total serum cholesterol levels in LDLR−/− mice transduced with shCtrl or shRaly for 6 
days (N=8(shCtrl), 7(shRaly)). b. Gene expression from liver harvested from LDLR−/− 
mice transduced with shCtrl or shRaly for 6 days (N=8(shCtrl), 7(shRaly)). All values are 
means ±SEM. c. Gene expression from C57Bl/6 mice transduced with Ctrl (AdGFP) or 
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LeXis (1.0 × 109 PFU) and shCtrl or shRaly (2.0 × 109 PFU) (N= 7(Ctrl/shCtrl and LeXis/
shRaly), 8(LeXis/shCtrl and Ctrl/shRaly)). All values are means ± SEM. d. Recruitment of 
Raly in promoter regions as determined by Chip analysis in livers transduced with control 
(AdGFP) or AdLeXis. Data expressed as percent input retrieved normalized to an upstream 
site (region1). (N=3/group). Values are means ± STD. * P < 0.05; ** P < 0.01; *** P < 
0.001; **** P < 0.0001 (unpaired two-tailed t-test (a,b,) and ANOVA with multigroup 
comparison (c)).
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Extended data Figure 10. Batch Genome Conversion between mouse and human at LeXis gene 
locus
Gene expression for human lincRNA TCONS 16452 in hepatocyte cell lines treated with 1 
µM GW3965. (N=3/group). Values are means ± SD. * P < 0.05; ** P < 0.01 and *** P 
<0.001 (unpaired two-tailed t-test).
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
 Acknowledgments
We thank members of the Tontonoz, Nagy, Smale and Black laboratories and the UCLA Atherosclerosis Research 
Unit for technical assistance and useful discussions. This work was support by NIH grants HL030568, HL066088, 
DK063491, HL128822, DK102559 and HL69766; American Heart Association grant 13POST17080115; American 
College of Cardiology Presidential CDA; and the UCLA Cardiovascular Discovery Fund (Lauren B. Leichtman and 
Arthur E. Levine Investigator Award).
References
1. Tontonoz P. Transcriptional and posttranscriptional control of cholesterol homeostasis by liver X 
receptors. Cold Spring Harbor symposia on quantitative biology. 2011; 76:129–137. [PubMed: 
21859674] 
2. Repa JJ, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) 
by oxysterol receptors, LXRalpha and LXRbeta. Genes & development. 2000; 14:2819–2830. 
[PubMed: 11090130] 
3. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-
dependent ubiquitination of the LDL receptor. Science. 2009; 325:100–104. [PubMed: 19520913] 
4. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis 
of a membrane-bound transcription factor. Cell. 1997; 89:331–340. [PubMed: 9150132] 
5. Zhang Y, et al. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and 
reverse cholesterol transport in mice. The Journal of clinical investigation. 2012; 122:1688–1699. 
[PubMed: 22484817] 
6. Creyghton MP, et al. Histone H3K27ac separates active from poised enhancers and predicts 
developmental state. Proceedings of the National Academy of Sciences of the United States of 
America. 2010; 107:21931–21936. [PubMed: 21106759] 
7. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 
489:57–74. [PubMed: 22955616] 
8. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. The 
Journal of clinical investigation. 2006; 116:607–614. [PubMed: 16511593] 
9. Vaisman BL, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary 
cholesterol excretion in transgenic mice. The Journal of clinical investigation. 2001; 108:303–309. 
[PubMed: 11457883] 
10. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol 
and fatty acid synthesis in the liver. The Journal of clinical investigation. 2002; 109:1125–1131. 
[PubMed: 11994399] 
11. Matsuda M, et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid 
synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes & development. 
2001; 15:1206–1216. [PubMed: 11358865] 
12. Hong C, et al. The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice. 
Cell metabolism. 2014; 20:910–918. [PubMed: 25440061] 
13. Carpenter S, et al. A long noncoding RNA mediates both activation and repression of immune 
response genes. Science. 2013; 341:789–792. [PubMed: 23907535] 
Sallam et al. Page 23
Nature. Author manuscript; available in PMC 2016 November 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates 
the Warburg effect. Molecular cell. 2014; 53:88–100. [PubMed: 24316222] 
15. Raal FJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL 
cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a 
randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375:998–1006. [PubMed: 
20227758] 
16. Gaudet D, et al. Targeting APOC3 in the familial chylomicronemia syndrome. The New England 
journal of medicine. 2014; 371:2200–2206. [PubMed: 25470695] 
17. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annual review of biochemistry. 
2012; 81:145–166.
18. Chu C, Quinn J, Chang HY. Chromatin isolation by RNA purification (ChIRP). Journal of 
visualized experiments : JoVE. 
19. Michaud EJ, Bultman SJ, Stubbs LJ, Woychik RP. The embryonic lethality of homozygous lethal 
yellow mice (Ay/Ay) is associated with the disruption of a novel RNA-binding protein. Genes & 
development. 1993; 7:1203–1213. [PubMed: 8319910] 
20. Jiang W, Guo X, Bhavanandan VP. Four distinct regions in the auxiliary domain of heterogeneous 
nuclear ribonucleoprotein C-related proteins. Biochimica et biophysica acta. 1998; 1399:229–233. 
[PubMed: 9765602] 
21. Okamura Y, et al. COXPRESdb in 2015: coexpression database for animal species by DNA-
microarray and RNAseq-based expression data with multiple quality assessment systems. Nucleic 
acids research. 2015; 43:D82–D86. [PubMed: 25392420] 
22. Seo YK, et al. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in 
autophagy. Cell metabolism. 2011; 13:367–375. [PubMed: 21459322] 
23. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein 
modeling, prediction and analysis. Nature protocols. 2015; 10:845–858. [PubMed: 25950237] 
24. Auboeuf D, et al. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional 
coactivation and RNA splicing. Molecular and cellular biology. 2004; 24:442–453. [PubMed: 
14673176] 
25. Rossi A, et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. 
Nature. 2015; 524:230–233. [PubMed: 26168398] 
26. Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. Conserved function of lincRNAs in vertebrate 
embryonic development despite rapid sequence evolution. Cell. 2011; 147:1537–1550. [PubMed: 
22196729] 
27. Sallam T, et al. The macrophage LBP gene is an LXR target that promotes macrophage survival 
and atherosclerosis. Journal of lipid research. 2014; 55:1120–1130. [PubMed: 24671012] 
28. Rong X, et al. LXRs Regulate ER Stress and Inflammation through Dynamic Modulation of 
Membrane Phospholipid Composition. Cell metabolism. 2013; 18:685–697. [PubMed: 24206663] 
29. Tarling EJ, Ahn H, de Aguiar Vallim TQ. The Nuclear Receptor FXR Uncouples the Actions of 
miR-33 From SREBP-2. Arteriosclerosis, thrombosis, and vascular biology. 2015; 35:787–795.
30. Hong C, et al. LXRalpha is uniquely required for maximal reverse cholesterol transport and 
atheroprotection in ApoE-deficient mice. Journal of lipid research. 2012; 53:1126–1133. 
[PubMed: 22454476] 
31. Seth PP, et al. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted 
nucleoside analogues show improved potency without increased toxicity in animals. Journal of 
medicinal chemistry. 2009; 52:10–13. [PubMed: 19086780] 
32. Bradley MN, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol 
overload in mice lacking LXR alpha and apoE. The Journal of clinical investigation. 2007; 
117:2337–2346. [PubMed: 17657314] 
33. Bhatt DM, et al. Transcript dynamics of proinflammatory genes revealed by sequence analysis of 
subcellular RNA fractions. Cell. 2012; 150:279–290. [PubMed: 22817891] 
34. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. 
Bioinformatics. 2009; 25:1105–1111. [PubMed: 19289445] 
Sallam et al. Page 24
Nature. Author manuscript; available in PMC 2016 November 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Trapnell C, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated 
transcripts and isoform switching during cell differentiation. Nature biotechnology. 2010; 28:511–
515.
36. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists 
using DAVID bioinformatics resources. Nature protocols. 2009; 4:44–57. [PubMed: 19131956] 
37. Carey MF, Peterson CL, Smale ST. Chromatin immunoprecipitation (ChIP). Cold Spring Harbor 
protocols. 2009; 2009 ppdb prot5279. 
38. Raj A, Tyagi S. Detection of individual endogenous RNA transcripts in situ using multiple singly 
labeled probes. Methods in enzymology. 2010; 472:365–386. [PubMed: 20580972] 
Sallam et al. Page 25
Nature. Author manuscript; available in PMC 2016 November 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. LXR activation inhibits cholesterol biosynthesis and induces LeXis expression
a. Real-time PCR analysis of gene expression in livers from C57BL/6 mice treated by oral 
gavage with 40 mg/kg GW3965 for the indicated time. N=6/group. Values are means ± 
SEM. All curves are statistically different from baseline expression (P < 0.05). b. Schematic 
representation of the LeXis gene locus on Integrative Genome Viewer (IGV) showing 
histone marks from LICR ENCODE data. c. Real-time PCR analysis of gene expression in 
primary mouse hepatocytes treated with GW3965 (GW, 1 µM) and/or the RXR ligand 
LG268 (LG, 50 nM). Results are representative of four independent experiments. Values are 
means ± SD. d. Real-time PCR analysis of gene expression in livers from male C57BL/6 
mice gavaged with GW3965 (40 mg/kg) prior to harvest at the indicated time (N=6/group). 
Values are means ± SEM. e. Gene expression in livers harvested from mice maintained on 
chow (N=2/group) or western diet (N=5/group). Values are means ± SEM. f. Gene 
expression in primary mouse peritoneal macrophages treated with GW3965 (GW, 1 µM) 
and/or LG268 (LG, 50 nM) for 16 hours. Results are representative of four independent 
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experiments. Values are means ± SD. * P < 0.05; ** P < 0.01 (ANOVA with multigroup 
comparison (a,d,e)).
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Figure 2. LeXis expression reduces serum cholesterol and sterol synthesis through a pathway 
requiring intact SREBP signaling
a. Total serum cholesterol levels in 10-week old chow-fed male C57Bl/6 mice transduced 
with adenoviral vectors encoding GFP control (Ad-GFP) or LeXis (Ad-LeXis) for 6 days 
(N=24/group). b. Total serum triglycerides levels in the mice shown in a (N=12–16/group). 
c. Cholesterol levels in pooled fractionated serum from mice treated with Ad-GFP or Ad-
LeXis. d. Analysis of gene expression in livers harvested after 6 days of transduction with 
Ad-GFP or Ad-LeXis (N=8/group). All values are means ± SEM. e. Total serum cholesterol 
levels in chow-fed male LDLR−/− mice (10 weeks old) transduced with Ad-GFP or Ad-
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LeXis for 6 days (N=8/group). f. Serum cholesterol levels in chow-fed WT or L-Scap KO 
mice gavaged with GW3965 40 mg/kg for 2 days. g. Cholesterol levels in pooled plasma 
fractions from mice shown in f. h. Total serum cholesterol levels in chow-fed L-Scap KO 
mice transduced with Ad-GFP or Ad-LeXis for 6 days. * P < 0.05; ** P < 0.01; *** P 
<0.001 and **** P <0.0001 (unpaired two-tailed t-test).
Sallam et al. Page 29
Nature. Author manuscript; available in PMC 2016 November 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Acute and chronic inactivation of LeXis alters hepatic lipid metabolism
a. Gene expression in livers from C57BL/6 mice on chow diet administered ASOs IP at 25 
mg/kg on days 1, 4, and 7, and gavaged with GW3965 at 40 mg/kg on days 4, 7 and 8 (N=5/
group). All values are means ± SEM. b. Total serum cholesterol from mice in a. c. Gene 
expression from C57BL/6 mice on chow diet administered ASOs IP at 25 mg/kg on days 1, 
3, and 5, and gavaged with GW3965 40 mg/kg on days 5 and 6 (N=8/group). All values are 
means ± SEM. d. Total serum cholesterol levels in chow-fed WT or LeXis−/− mice gavaged 
with GW3965 40 mg/kg for 2 days (N=8–10/group). e. Gene expression from C57BL/6 WT 
or LeXis−/− mice on chow diet gavaged with GW3965 40 mg/kg for 2 days (N=8–10/
group). All values are means ± SEM. f. Hepatic cholesterol content normalized to liver mass 
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from C57BL/6 WT or LeXis−/− mice fed western diet for 3 weeks (N=7–11/group). All 
values are means ± SEM. g. Representative (of 3 images per group) gross appearance of 
livers from WT and LeXis−/− after 3 weeks on western diet. h. Histologic sections of liver 
from WT and LeXis−/− after 3 weeks western diet (hematoxylin and eosin stain 
representative of 3 images per group). * P < 0.05; ** P < 0.01; *** P <0.001 and **** P 
<0.0001 (ANOVA (b, c) and unpaired two-tailed t-test (e,f)).
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Figure 4. LeXis interacts with Raly to regulate metabolic gene expression
a. Hepa1-6 cells were transfected with LeXis and 24 h later cellular content was separated 
into cytoplasmic soluble, nuclear soluble and insoluble (pellet) fractions. Transcripts in each 
fraction were analyzed by real-time PCR, and fraction purity was validated by Western 
blotting with the indicated compartment markers. Cyt=Cytoplasm, Nuc=Nucleoplasm, 
Pel=Nuclear Pellet. (N=3/group). Values are means ± STD. b. Representative (of 3) 
micrograph showing LeXis subcellular localization in primary mouse hepatocytes by single 
molecule fluorescence in situ hybridization using anti-sense probes to LeXis (Red). Nuclei 
were counterstained with DAPI (blue). c. Recruitment of RNA polymerase II to promoter 
regions as determined by ChIP-qPCR analysis in livers transduced with control (AdGFP) or 
AdLeXis. Data are expressed as percent input retrieved normalized to an upstream site 
(region1). (N=3/group). Values are means ± STD. d. Total serum cholesterol levels in 14-
week old chow-fed male C57BL/6 mice transduced with control (shCtrl) or adenoviral 
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vectors expressing shRNA targeting Raly (shRaly) (N=8/group). e. Gene expression in livers 
of the mice shown in f. Values are means ± SEM. f. Total serum cholesterol in chow-fed 
male C57BL/6 mice transduced with control (AdGFP) or AdLeXis (1.0 × 109 PFU) and 
shCtrl or shRaly (2.0 × 109 PFU) (N= 7–8/group). * P < 0.05; ** P < 0.01; *** P < 0.001 
(unpaired two-tailed t-test (d,e) and ANOVA with multigroup comparison (f)).
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